SCHEMBL2860140

SCHEMBL2860140

COc1ccc(-c2ncc(Br)cn2)cc1F

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 3/20 0.55
PDGFRA P16234 3/20 0.55
RAB9A P51151 4/20 0.46
ALDH1A1 P00352 4/20 0.46
NPC1 O15118 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
CYP17A1 P05093 1/20 0.46
IDO1 P14902 1/20 0.43
TDO2 P48775 1/20 0.43
MAPK1 P28482 2/20 0.42
LMNA P02545 2/20 0.42
HTT P42858 1/20 0.42
KDM4E B2RXH2 3/20 0.42
AR P10275 1/20 0.42
GLA P06280 1/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30103027 0.83 PDGFRB (0.51) PDGFRBPDGFRARAB9AALDH1A1NPC1
SCHEMBL19876623 0.81 PDGFRB (0.55) PDGFRBPDGFRARAB9AALDH1A1NPC1
SCHEMBL24785367 0.80 PDGFRB (0.51) PDGFRBPDGFRARAB9AALDH1A1NPC1
SCHEMBL7783072 0.79 CYP17A1 (0.57) PDGFRBPDGFRARAB9AALDH1A1NPC1
SCHEMBL24064535 0.79 S1PR1 (0.51) ALDH1A1MAPTHPGDS
SCHEMBL2854186 0.77 PDGFRB (0.48) PDGFRBPDGFRAALDH1A1MEN1KMT2A
SCHEMBL8611753 0.77 XDH (0.49) RAB9ANPC1SMN1; SMN2ERN1
SCHEMBL9464193 0.76 CYP17A1 (0.61) PDGFRBPDGFRARAB9AALDH1A1NPC1
SCHEMBL31288176 0.75 PTPN1 (0.51) PDGFRBPDGFRARAB9AALDH1A1NPC1
SCHEMBL9815140 0.75 RARB (0.52) PDGFRBPDGFRARAB9AALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1827434-B1 QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER AMGEN INC (US) 2014-01-15 EP disclosed
US-7652009-B2 Substituted heterocycles and methods of use AMGEM INC. (US) 2010-01-26 US disclosed
EP-1827434-A2 QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER Amgen Inc. (US) 2007-09-05 EP disclosed
US-20060252777-A1 Substituted heterocycles and methods of use AMGEN INC. (US) 2006-11-09 US disclosed
WO-2006060318-A2 QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER AMGEN INC. (US) 2006-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252777-A1 Substituted heterocycles and methods of use HGF, HGFAC, MET PDGFRB 21/4885PDGFRA 26/4885RAB9A 1707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.